Dov Goldstein

Dov A. Goldstein currently works at ADMA Plasma Biologics, Inc., as Director, Gain Therapeutics, Inc., as Independent Director from 2021, Coya Therapeutics, Inc., as Independent Director from 2021, and BioAge Labs, Inc., as Chief Financial Officer from 2021.
Dr. Goldstein also formerly worked at MIA Dynamics Motors Ltd., as Chairman & Chief Executive Officer from 2006 to 2014, RIGImmune, Inc., as President, CEO, Treasurer & Director from 2018 to 2020, NeuBase Therapeutics, Inc., as Chairman from 2022 to 2025, Esperion Therapeutics, Inc., as Independent Director from 2008 to 2019, Cempra Pharmaceuticals, Inc., as Director from 2009 to 2013, Topaz Pharmaceuticals, Inc., as Director, ADMA Biologics, Inc., as Independent Non-Executive Director from 2007 to 2020, Cempra, Inc., as Director from 2008 to 2011, HealthCare Ventures LLC, as Director-Venture Analysis, Global Pay (P.C.S) Ltd., as Director, Scerene Healthcare, Inc., as Director, Durata Therapeutics, Inc., as Interim Co-President & Independent Director from 2009 to 2012, Neubase Therapeutics, Inc., as Director, Geom Therapeutics, Inc., as Director, Vicuron Pharmaceuticals LLC, as Chief Financial Officer & Executive Vice President from 2001 to 2005, Aisling Capital LLC, as Operating Partner from 2006 to 2019, Schrödinger, Inc., as Chief Financial Officer from 2017 to 2018, RCMC Capital LLP, as Managing Partner from 2014 to 2019, Loxo Oncology, Inc., as Chief Financial Officer from 2014 to 2015, and Indapta Therapeutics, Inc., as Chief Financial & Business Officer from 2020 to 2021.
Dr. Goldstein received his undergraduate degree in 1990 from Stanford University, Masters Business Admin degree from Columbia Business School, and doctorate degree from Yale School of Medicine.